微量白蛋白尿组发生联合终点事件的机率较正常UACR组高43%。
Patients with microalbuminuria were 43 percent more likely to reach the combined end point than those with normal UACR.
巨量白蛋白尿的患者组，其肾病进展的危险因素与微量白蛋白尿组相似，其进展的患者肾小球滤过率较低（GFRs）且诊断有心血管疾病或心力衰竭。
The macroalbuminuria group had risk factors similar to the microalbuminuria group, and had lower glomerular filtration rates (GFRs) and a diagnosis of cardiovascular disease or heart failure.
但之后统计的数据均提示，奥美沙坦组出现微量白蛋白尿的患者少于安慰剂组。
For the remainder of the study, fewer patients in the olmesartan group experienced microalbuminuria, compared with patients in the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
应用推荐